-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

Benzinga·08/31/2026 13:07:01
Listen to the news
RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.